UA41909C2 - Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат - Google Patents

Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат

Info

Publication number
UA41909C2
UA41909C2 UA95073400A UA95073400A UA41909C2 UA 41909 C2 UA41909 C2 UA 41909C2 UA 95073400 A UA95073400 A UA 95073400A UA 95073400 A UA95073400 A UA 95073400A UA 41909 C2 UA41909 C2 UA 41909C2
Authority
UA
Ukraine
Prior art keywords
osteoporosis
inhibition
combination
compounds
pharmaceutical agent
Prior art date
Application number
UA95073400A
Other languages
English (en)
Russian (ru)
Inventor
Ларрі Джон БЛЕК
Ларри Джон БЛЭК
Джордж Джозеф Каллінан
Джордж Джозеф КАЛЛИНАН
Original Assignee
Елі Ліллі Енд Компані
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані, Эли Лилли Энд Компани filed Critical Елі Ліллі Енд Компані
Publication of UA41909C2 publication Critical patent/UA41909C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід належить до галузі медицини. Застосування комбінації першої сполуки, вибраної з 2-фенил-3-ароілбензотіофенів, і другої сполуки, представленої бісфосфонатом, або їх фармацевтично прийнятних солей і сольватів для інгібування остеопорозу.
UA95073400A 1994-07-22 1995-07-19 Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат UA41909C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27936394A 1994-07-22 1994-07-22

Publications (1)

Publication Number Publication Date
UA41909C2 true UA41909C2 (uk) 2001-10-15

Family

ID=23068631

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95073400A UA41909C2 (uk) 1994-07-22 1995-07-19 Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат

Country Status (23)

Country Link
US (1) US20010051636A1 (uk)
EP (1) EP0693285B1 (uk)
JP (1) JPH0840911A (uk)
KR (1) KR960003726A (uk)
CN (1) CN1079671C (uk)
AT (1) ATE212846T1 (uk)
AU (1) AU693235B2 (uk)
BR (1) BR9503406A (uk)
CA (1) CA2154414A1 (uk)
CZ (1) CZ189195A3 (uk)
DE (1) DE69525291T2 (uk)
DK (1) DK0693285T3 (uk)
ES (1) ES2168336T3 (uk)
HU (1) HUT72754A (uk)
IL (1) IL114683A (uk)
NO (1) NO308194B1 (uk)
NZ (1) NZ272608A (uk)
PL (1) PL181304B1 (uk)
PT (1) PT693285E (uk)
RU (1) RU2149631C1 (uk)
TW (1) TW398975B (uk)
UA (1) UA41909C2 (uk)
ZA (1) ZA956029B (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU712711B2 (en) * 1994-11-29 1999-11-11 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
CA2206422A1 (en) * 1994-11-29 1996-06-06 Hoechst Marion Roussel, Inc. Method of using triaryl-ethylene derivatives in the treatment and prevention of osteoporosis
EP0722727A1 (en) * 1995-01-20 1996-07-24 Eli Lilly And Company Benzofuran derivatives for inhibiting uterine fibroid disease
US5554600A (en) * 1995-01-20 1996-09-10 Eli Lilly And Company Methods for inhibiting endometriosis
US5512583A (en) * 1995-01-30 1996-04-30 Eli Lilly And Company Methods of decreasing serum calcium levels
US6479517B1 (en) * 1995-02-28 2002-11-12 Eli Lilly And Company Phosphorous-containing benzothiophenes
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5958969A (en) * 1996-10-10 1999-09-28 Eli Lilly And Company Benzo b!thiophene compounds, intermediates, formulations, and methods
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2001272916A1 (en) * 2000-07-19 2002-02-05 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
DK3260117T3 (da) * 2003-09-12 2019-07-01 Amgen Inc Hurtigt opløsende formulering, der omfatter cinacalcet-hcl
KR100557086B1 (ko) * 2003-11-14 2006-03-03 한미약품 주식회사 랄록시펜과 비스포스포네이트의 상호 염
WO2005079811A1 (en) * 2004-02-19 2005-09-01 Teva Pharmaceutical Industries Ltd. Improved therapy using a combination of raloxifene and alendronate
FR2875807B1 (fr) * 2004-09-30 2006-11-17 Servier Lab Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
AU2006210572B2 (en) 2005-02-03 2011-08-04 The General Hospital Corporation Method for treating gefitinib resistant cancer
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2725598C (en) 2008-06-17 2013-10-08 Wyeth Llc Antineoplastic combinations containing hki-272 and vinorelbine
WO2010017163A1 (en) 2008-08-04 2010-02-11 Wyeth Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine
KR20140036332A (ko) 2009-04-06 2014-03-25 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
EP3426062A1 (en) * 2016-03-10 2019-01-16 Enzymotec Ltd. Lipid compositions and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
BE637389A (uk) 1962-09-13
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4323707A (en) 1975-10-28 1982-04-06 Eli Lilly And Company Antifertility compounds
US4230862A (en) 1975-10-28 1980-10-28 Eli Lilly And Company Antifertility compounds
US4400543A (en) 1975-10-28 1983-08-23 Eli Lilly And Company 3-Phenyl-4-benzoyl-1,2-dihydronaphthalenes
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5139786A (en) 1989-07-07 1992-08-18 Ciba-Geigy Corporation Topical formulations
DE69023844T2 (de) 1989-09-06 1996-06-20 Merck & Co Inc Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
EP0470310B1 (en) 1990-08-09 1995-11-29 Council of Scientific and Industrial Research Novel benzopyrans and process for their production
JPH04312526A (ja) 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5591753A (en) * 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis

Also Published As

Publication number Publication date
PL181304B1 (pl) 2001-07-31
CN1119940A (zh) 1996-04-10
TW398975B (en) 2000-07-21
AU2711295A (en) 1996-02-01
DK0693285T3 (da) 2002-05-27
JPH0840911A (ja) 1996-02-13
US20010051636A1 (en) 2001-12-13
NO952890L (no) 1996-01-23
CA2154414A1 (en) 1996-01-23
ZA956029B (en) 1997-01-20
NO952890D0 (no) 1995-07-20
NO308194B1 (no) 2000-08-14
EP0693285A2 (en) 1996-01-24
EP0693285A3 (en) 1998-05-06
ES2168336T3 (es) 2002-06-16
ATE212846T1 (de) 2002-02-15
NZ272608A (en) 2000-05-26
PL309693A1 (en) 1996-02-05
DE69525291D1 (de) 2002-03-21
HUT72754A (en) 1996-05-28
HU9502193D0 (en) 1995-09-28
DE69525291T2 (de) 2002-09-19
PT693285E (pt) 2002-06-28
KR960003726A (ko) 1996-02-23
IL114683A (en) 2001-06-14
CN1079671C (zh) 2002-02-27
RU2149631C1 (ru) 2000-05-27
EP0693285B1 (en) 2002-02-06
BR9503406A (pt) 1996-02-27
IL114683A0 (en) 1995-11-27
CZ189195A3 (en) 1996-06-12
AU693235B2 (en) 1998-06-25

Similar Documents

Publication Publication Date Title
UA41909C2 (uk) Використання комбінації сполук для інгібірування остеопорозу, фармацевтичний препарат
MX9706449A (es) Composicion farmaceutica para compuestos de piperidinalcanol.
IL127244A0 (en) Pharmaceutical for treatment of neurological and neuropsychiatric disorders
MY118151A (en) Pharmaceutical formulations containing voriconazole.
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
DE69413237D1 (en) Plättchenaggregationsinhibitoren
IL101358A0 (en) Crystalline tiagabine hydrochloride monohydrate,its preparation and pharmaceutical compositions containing it
GEP20063719B (en) Prevention of Migraine Recurrence
IL113365A (en) 5-Heterocyclo-1,5-benzodiazepine derivatives their preparation and pharmaceutical compositions containing them
IL105475A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING 1a, 24(R) - DIHYDROXY-22(E)-DEHYDRO- VITAMIN D3 FOR TREATING OSTEOPOROSIS
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
NZ515685A (en) Use of riluzole for the treatment of multiple sclerosis
EP0869786A4 (en) PHARMACEUTICAL COMPOUNDS
IL100955A (en) Amino-polyhydroxy- cyclopentane derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
IL109866A0 (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) l-hydrogentartrate, its preparation and pharmaceutical compositions containing it
BG106151A (en) Pharmaceutical complex
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
HU9500175D0 (en) Pharmacologically active alpha-[tertiary-aminomethyl]-benzenemethanol derivatives
EP0824341A4 (en) PREVENTING TOOTH LOSS THROUGH ADMINISTRATION OF ALENDRONATE OR ITS SALTS
MY124089A (en) Use of cetirizine for preventing the onset of asthma
AU1884895A (en) Use of phosphorus derivatives of alkaloids for treating endocrinopathies
NZ290236A (en) Inhibition ofleucotriene biosynthesis and pharmaceutical compositions comprising aryl-urea derivatives
NO964921D0 (no) Mellomprodukt for fremstilling av farmasöytisk aktiv forbindelse
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.
IL143264A0 (en) A combination of a histamine h2 receptor blocker or a proton pump inhibitor and a bisphosphonate or pharmaceutically acceptable salts thereof or mixtures thereof, for use as a medicament, for use in the manufacture of a medicament, pharmaceutical compositions and kits comprising any thereof, all for inhibiting bone resorption